Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Clin Cancer Res. 2022 Jul 1;28(13):2779–2788. doi: 10.1158/1078-0432.CCR-21-2389

Table 2.

Predictive effects of PlGF and VEGF-D.

OS PFS
Chemo pooled Chemo pooled
Biomarker Bev Cetux Pintx Bev Cetux Pintx
PlGF 1.65 (1.16–2.36) 1.12 (0.83–1.51) 0.1157 PlGF 1.51 (1.10–2.06) 0.94 (0.71–1.25) 0.0298
VEGF-D 1.31 (0.98–1.74) 1.12 (0.84–1.50) 0.4346 VEGF-D 1.34 (1.03–1.73) 0.97 (0.75–1.27) 0.1069
FOLFIRI FOLFIRI
PlGF 1.47 (0.74–2.94) 0.84 (0.45–1.57) 0.2079 PlGF 1.34 (0.71–2.51) 0.80 (0.46–1.41) 0.2487
VEGF-D 0.84 (0.49–1.45) 1.10 (0.54–2.26) 0.5643 VEGF-D 0.95 (0.61–1.48) 1.37 (0.73–2.56) 0.4336
FOLFOX FOLFOX
PlGF 1.71 (1.13–2.59) 1.23 (0.88–1.71) 0.2540 PlGF 1.56 (1.08–2.24) 0.99 (0.72–1.37) 0.0656
VEGF-D 1.65 (1.17–2.33) 1.12 (0.81–1.54) 0.1151 VEGF-D 1.70 (1.19–2.42) 0.92 (0.68–1.24) 0.0097

Note: median overall survival or progression-free survival time are presented in months, with 95% confidence intervals in parenthesis. Abbreviations: Bev, bevacizumab; Cetux, cetuximab; Pintx, interaction p value.